Olympus Corporation

Insights on the Rotator Cuff Injury Treatment Global Market to 2027 - Featuring 3S Ortho, Anika Therapeutics, Arthrex and BREG Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 7, 2022
Health, General Health, Olympus Corporation, Decision-making, Acquisition, DJO, USD, Treatment, Ortho, Strategic management, Value, R, Business Growth Fund, COVID-19, Customer support, Growth, Smith & Nephew, LLC, Investment, Certification, CAGR, Stryker Corporation, Use, Rotator cuff, A, Agriculture, Retail, Medical device, Physical therapy, Injury, Medication

What are the inhibiting factors and impact of COVID-19 shaping the Global Rotator Cuff Injury Treatment Market during the forecast period?

Key Points: 
  • What are the inhibiting factors and impact of COVID-19 shaping the Global Rotator Cuff Injury Treatment Market during the forecast period?
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Rotator Cuff Injury Treatment Market?
  • What is the market share of the leading vendors in the Global Rotator Cuff Injury Treatment Market?
  • What modes and strategic moves are considered suitable for entering the Global Rotator Cuff Injury Treatment Market?

With Market Size Valued at $5.3 Billion by 2026, it`s a Healthy Outlook for the Global Optical Measurement Equipment Market

Retrieved on: 
Monday, June 27, 2022
Olympus Corporation, Nikon, Personal Software Services, Zygo Corporation, Hexagon AB, Research, Intelligence, Marketing, COVID-19, Optics, Geography, Growth, Forecasting, Mitutoyo, GIA, Internet, Carl Zeiss AG, Bowers Group, SAN, Software, CAGR, GOM, Players, Pet, Pharmaceutical industry, Others

SAN FRANCISCO, June 27, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Optical Measurement Equipment - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, June 27, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Optical Measurement Equipment - Global Market Trajectory & Analytics" .
  • Geographies:World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
  • Preview Registry
    Amid the COVID-19 crisis, the global market for Optical Measurement Equipment estimated at US$3.8 Billion, is projected to reach a revised size of US$5.3 Billion by 2026, growing at a CAGR of 5.4% over the analysis period.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

Valued to be $944.7 Million by 2026, Ingestible Sensors Slated for Robust Growth Worldwide

Retrieved on: 
Thursday, June 23, 2022
Temperature, CAGR, COVID-19, Players, Intelligence, Forecasting, Olympus Corporation, GIA, Research, Medicine, Growth, Hot Particulate Ingestion Rig, Marketing, Internet, Fitness, SAN, Sport, Pharmaceutical industry, Pet, Pressure, Others

Companies:42 - Players covered include Capsovision, Inc.; Hq, Inc.; Mc10, Inc.; Microchips Biotech, Inc.; Olympus Corporation; Proteus Digital Health, Inc. and Others.

Key Points: 
  • Companies:42 - Players covered include Capsovision, Inc.; Hq, Inc.; Mc10, Inc.; Microchips Biotech, Inc.; Olympus Corporation; Proteus Digital Health, Inc. and Others.
  • Preview Registry
    Amid the COVID-19 crisis, the global market for Ingestible Sensors estimated at US$398.7 Million, is projected to reach a revised size of US$944.7 Million by 2026, growing at a CAGR of 14.8% over the analysis period.
  • The U.S. Market is Estimated at $128.5 Million in 2021, While China is Forecast to Reach $198 Million by 2026
    The Ingestible Sensors market in the U.S. is estimated at US$128.5 Million in the year 2021.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

Global Anesthesia and Respiratory Devices Market Report 2022: Market is Expected to Grow to $82.25 Billion in 2026 at a CAGR of 12.4% - Forecast to 2031 - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 26, 2022
Medical Devices, Health, Fisher & Paykel Healthcare, Smartphone, Patient, 3M, Breathing, Degenerative disease, Asia-Pacific, Boston Scientific, Torso, Teleflex, Anesthesia, Medtronic, Getinge Group, Hospital, Organization, Workload, Olympus Corporation, Diagnosis, Medical device, ResMed

The "Global Anesthesia And Respiratory Devices Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anesthesia And Respiratory Devices Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The anesthesia and respiratory devices market consists of sales of anesthesia and respiratory devices and related services by entities (organizations, sole traders, and partnerships) that produce anesthesia and respiratory devices used in the diagnosis and treatment of respiratory diseases.
  • The main types of anesthesia and respiratory devices are respiratory devices and equipment (therapeutic and diagnostic), anesthesia machines, anesthesia disposables, and respiratory disposables.
  • The preference for wearable and portable medical devices is increasing and companies in the respiratory devices market are developing wearable respiratory devices to improve patient monitoring.

Operating Room/OR Integration Market worth $3.3 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, May 25, 2022
Product, Risk, Hospital, Steris, Integrated Medical Systems International, Surgeon, Vital signs, Efficiency, Getinge Group, Communication, Vital, Olympus Corporation, Stryker Corporation, Adoption, CAGR, Patient safety, Medical device, Health insurance, Technology, Growth, Telemetry

By component, the software segment accounted for the largest share of the operating room integration market in 2021.

Key Points: 
  • By component, the software segment accounted for the largest share of the operating room integration market in 2021.
  • The software segment is estimated to have the largest share by value of the operating room integration market.
  • The orthopedic surgery segment is expected to witness the highest growth rate in the operating room integration market, by application.
  • North America accounted for the largest share of the OR Integration market in 2021, followed by Europe and Asia Pacific.

Operating Room/OR Integration Market worth $3.3 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Wednesday, May 25, 2022
Product, Risk, Hospital, Steris, Integrated Medical Systems International, Surgeon, Vital signs, Efficiency, Getinge Group, Communication, Vital, Olympus Corporation, Stryker Corporation, Adoption, CAGR, Patient safety, Medical device, Health insurance, Technology, Growth, Telemetry

By component, the software segment accounted for the largest share of the operating room integration market in 2021.

Key Points: 
  • By component, the software segment accounted for the largest share of the operating room integration market in 2021.
  • The software segment is estimated to have the largest share by value of the operating room integration market.
  • The orthopedic surgery segment is expected to witness the highest growth rate in the operating room integration market, by application.
  • North America accounted for the largest share of the OR Integration market in 2021, followed by Europe and Asia Pacific.

Olympus Supports CMS Coverage Decision for Lung Cancer Screening

Retrieved on: 
Tuesday, May 24, 2022
People, Laparoscopy, Disease, Method, Lung cancer, American College of Chest Physicians, PJ, Olympus Corporation, Center, Lymph, Lammers, Physician, Rose M. Likins, Medicaid, Lung, American Lung Association, Quality of life, Ultrasound, NSCLC, Research, Medicare, Neoplasm, Large-cell lung carcinoma, PMID, Centers for Medicare & Medicaid Services, CMS, American College, Survival, CM, Multimedia, Smoker, Mediastinoscopy, Endoscopy, EBUS, Awareness, Kątki, Mediastinum, United States Preventive Services Task Force, Olympus, Patient, User experience, Survival rate, Decision-making, USPSTF, Lung cancer staging, Veni, vidi, vici, Prognosis, Diagnosis, Health insurance, Medical imaging, Medical device, Mobile phone, Silviculture, Medicine

CENTER VALLEY, Pa., May 24, 2022 /PRNewswire/ -- Olympus, a global leader in designing and delivering innovative medical technology solutions, announced its support for the Centers for Medicare & Medicaid Services (CMS) decision to expand lung cancer screening eligibility for those covered by Medicare.

Key Points: 
  • CENTER VALLEY, Pa., May 24, 2022 /PRNewswire/ -- Olympus, a global leader in designing and delivering innovative medical technology solutions, announced its support for the Centers for Medicare & Medicaid Services (CMS) decision to expand lung cancer screening eligibility for those covered by Medicare.
  • Earlier screening and detection may save the lives of those diagnosed with non-small cell lung cancer," said Paul Skodny, Executive Director of Global Health Economics and Market Access at Olympus Corporation of the Americas.
  • "Still, there is much work to be done to align CMS coverage through Medicare and Medicaid with lung cancer screening guidance so that the barriers to screening are eliminated."
  • Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.

Study Results Show Long-term Efficacy of iTind Procedure

Retrieved on: 
Wednesday, May 18, 2022
Urination, Laparoscopy, Olympus, Quality of life, Quality, Blood, Urine, Time-invariant system, Multimedia, Patient, Prostate, View, BPH, International Prostate Symptom Score, Clinical study design, Treatment, Endoscopy, Urology, DOI, EMEA, IPSS, Man, Lower urinary tract symptoms, AUA, University, Ageing, Olympus Corporation, Urinary tract infection, MD, University of Turin, Medical imaging, Medical device

CENTER VALLEY, Pa. and HAMBURG, Germany, May 18, 2022 /PRNewswire/ -- Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today the summary results of a follow-up study to measure the durability of the iTind™ procedure for treating the lower urinary tract symptoms caused by BPH (benign prostatic hyperplasia). The abstract was presented at the American Urological Association Annual Meeting (AUA) on May 15, 2022.1

Key Points: 
  • "The data demonstrate that the iTind procedure is a safe and effective treatment for BPH symptoms that is durable over time."
  • "These study results are highly anticipated by urologists, which was confirmed by the high interest in the iTind device at the Olympus booth at the 2022 AUA meeting," said Vanessa Malka, Executive Director and iTind Commercial Head for Olympus Corporation.
  • "The results demonstrate that the iTind procedure is an alternative to current BPH therapies.
  • More information about the iTind procedure in the U.S. is available at BPHTherapy.com/iTind and in the EMEA region at olympus-europa.com/medical/en/Products-and-Solutions/Products/Product/iTind.html .

Study Results Show Long-term Efficacy of iTind Procedure

Retrieved on: 
Wednesday, May 18, 2022
Urination, Laparoscopy, Olympus, Quality of life, Quality, Blood, Urine, Time-invariant system, Patient, Prostate, BPH, International Prostate Symptom Score, Clinical study design, Treatment, Endoscopy, Urology, DOI, EMEA, IPSS, Man, Lower urinary tract symptoms, AUA, University, Ageing, Olympus Corporation, Urinary tract infection, MD, University of Turin, Medical imaging, Medical device

CENTER VALLEY, Pa. and HAMBURG, Germany, May 18, 2022 /PRNewswire/ -- Olympus, a leading global medtech company providing innovative solutions for medical and surgical procedures, announced today the summary results of a follow-up study to measure the durability of the iTind™ procedure for treating the lower urinary tract symptoms caused by BPH (benign prostatic hyperplasia). The abstract was presented at the American Urological Association Annual Meeting (AUA) on May 15, 2022.1

Key Points: 
  • "The data demonstrate that the iTind procedure is a safe and effective treatment for BPH symptoms that is durable over time."
  • "These study results are highly anticipated by urologists, which was confirmed by the high interest in the iTind device at the Olympus booth at the 2022 AUA meeting," said Vanessa Malka, Executive Director and iTind Commercial Head for Olympus Corporation.
  • "The results demonstrate that the iTind procedure is an alternative to current BPH therapies.
  • More information about the iTind procedure in the U.S. is available at BPHTherapy.com/iTind and in the EMEA region at olympus-europa.com/medical/en/Products-and-Solutions/Products/Product/iTind.html .

iTind Procedure Wins Gold and Silver Medtech Awards

Retrieved on: 
Friday, May 13, 2022
Laparoscopy, Edison Awards, Olympus, Engineering, Blood, Association for the Behavioral Sciences and Medical Education, Urine, Medicine, Multimedia, Prostate, Patient, Science, Solution, BPH, Quality of life, Treatment, Endoscopy, Urology, Man, Safety, Emergency Medical Treatment and Active Labor Act, Gastrointestinal tract, Olympus Corporation, Urinary tract infection, Gold, Medical device, Pharmaceutical industry, Medical imaging, Birth control, Silver

CENTER VALLEY, Pa., May 13, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today that its iTind™ procedure for the treatment of enlarged prostate won Gold in the 2022 Medical Design Excellence Awards and Silver in the 2022 Edison Awards.

Key Points: 
  • CENTER VALLEY, Pa., May 13, 2022 /PRNewswire/ -- Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, announced today that its iTind procedure for the treatment of enlarged prostate won Gold in the 2022 Medical Design Excellence Awards and Silver in the 2022 Edison Awards.
  • Nominated within the Science and Medical category for Medical Treatments, the iTind procedure was recognized by the Edison Awards, which highlights innovation and innovators whose solutions make a positive impact in the world.
  • Treatment with the iTind procedure takes five to seven days and works by reshaping the prostate.
  • As with any medical procedure, the iTind procedure comes with possible side effects, including pelvic discomfort, blood in urine, painful or urgent urination.